In Vivo Gene Therapies in VR
REGENXBIO is developing in vivo gene therapies using Adeno-associated viruses (AAV) from their NAV® Technology Platform to treat rare and common diseases.
Using captivating scientific visuals, the animation illustrates the science behind the NAV® Technology Platform, equipping Medical Affairs and Investor Relations teams with vibrant and colorful 3D graphics that make this scientific concept clear and engaging.
Imagery from the animation was used at REGENXBIO’s booth, creating a scientific backdrop that ties in with the visuals and key messages from the animation, resulting in an eye-catching booth that enticed passers-by and helped develop a consistent brand identity.
In addition, our interactive team produced a virtual reality (VR) experience and holographic fan content to be used at industry conferences.
The VR immersed the viewer within the NAV® Technology Platform in an exciting and creative way. A holographic fan was also incorporated into the booth to show animation assets in an eye-catching format.
The assets were used at the 18th Annual WORLDSymposium™ and the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference..
Are you interested in seeing how our award-winning virtual reality can help you?
Random42 strives to remain at the forefront of interactive technology. Get in touch for a consultation on your next project.